Novo's semaglu­tide shows po­ten­tial in chron­ic skin con­di­tion in obese pa­tients

A small study con­duct­ed by re­searchers at St. Vin­cent’s Uni­ver­si­ty Hos­pi­tal in Dublin sug­gests that No­vo Nordisk’s GLP-1 semaglu­tide could treat a com­mon and chron­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER